-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Screenshot Source: CDE official website ZM25 is an anti-HER2 antibody developed by Zymeworks based on its Azymetri platform.
November 2018, The state acquired exclusive development and commercial rights to ZM25 and another drug in development in Asia (excluding Japan), Australia and New Zealand with a down payment of up to $40 million and a milestone payment of up to $390 million.
as a dual-specific antibody, the ZW25 can bind to two non-overlapping HER2 cousins at the same time, i.e. double complementary bits.
this unique design creates a variety of mechanisms of action, including double blocking of HER2 signals, enhanced binding and removal of HER2 proteins from cell surfaces, and powerful antibody effect cell function to enhance anti-tumor activity in patients.
the FDA has granted the orphan drug, which is used to treat stomach and ovarian cancer, as well as first-line fast-track eligibility for the treatment of gastroesophageal adenocarcinoma.
public information, Zymeworks is developing ZW25 as a HER2 targeted therapy for treating patients with any HER2 expression solid tumor.
November 2019, ZW25 presented a Phase 1 clinical data at the ESMO-Asia 2019 Conference, with a comprehensive disease control rate of 70.2% for 69 subjects involving more than 10 solid tumors.
: Screenshot of Zymeworks' official website shows that the product has the highest objective response rate in bile tube cancer (up to 66.7%) and a disease control rate of 78.8%.
response rates in rectal and stomach cancers were 46% and 39%, respectively.
, confirmed reactions can also be seen in other types of tumors, including a 100% reduction in target lesions in pancreatic cancer patients.
the medium non-progress life of 5.5 months and is still under continuous evaluation.
Based on the third-quarter financial results announced by Baiji Shenzhou, the company is currently working with Zymeworks on post-clinical development and has launched a registered clinical trial for the treatment of patients with advanced or metastatic HER2 gene amplification bile gallbladder cancer.
: The Drug Review Center of the State Drug Administration of China. Retrieved Nov 16, 2020, from s2 Safety, Anti-Tumor Activity, and Biomarker Results of the HER2-Targeted Bispecific Antibody ZW25 in HER2-Expressing Solid Tumor (#61O) Retrieved Nov 22, 2019.from .3, Zymeworks and Baiji Shenzhou announced the signing of HER2 Targeted Therapeutic Candidate Drugs, ZW25 and ZW49, a licensing agreement in the Asia Pacific region, and a global research and development partnership to establish the Azymetric™ and EFECT™ platforms. Retrieved November 27, 2018, from Source: Medical Mission Hills